Lucid Diagnostics (LUCD)
(Delayed Data from NSDQ)
$0.82 USD
-0.03 (-3.31%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $0.80 -0.02 (-2.32%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Lucid Diagnostics Inc. (LUCD) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$3.75 | $7.50 | $2.50 | 341.18% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Lucid Diagnostics Inc. comes to $3.75. The forecasts range from a low of $2.50 to a high of $7.50. The average price target represents an increase of 341.18% from the last closing price of $0.85.
Analyst Price Targets (6 )
Broker Rating
Lucid Diagnostics Inc. currently has an average brokerage recommendation (ABR) of 1.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.40 a month ago based on five recommendations.
Of the six recommendations deriving the current ABR, four are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 66.67% and 33.33% of all recommendations. A month ago, Strong Buy made up 60%, while Buy represented 40%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/LUCD.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 3 | 3 | 3 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.33 | 1.33 | 1.40 | 1.40 | 1.40 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/13/2024 | Canaccord Genuity | Kyle Mikson | Not Available | Strong Buy |
8/13/2024 | Needham & Company | Michael Matson | Moderate Buy | Moderate Buy |
6/6/2024 | Ascendiant Capital Markets | Edward M Woo | Moderate Buy | Moderate Buy |
3/1/2024 | Cantor Fitzgerald & Co | Ross Osborn | Strong Buy | Strong Buy |
3/1/2024 | Maxim Group | Anthony V Vendetti | Not Available | Strong Buy |
1/7/2024 | BTIG | Mark Massaro | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.33 |
ABR (Last week) | 1.33 |
# of Recs in ABR | 6 |
Average Target Price | $3.75 |
LT Growth Rate | NA |
Industry | Medical - Instruments |
Industry Rank by ABR | 81 of 253 |
Current Quarter EPS Est: | NA |